Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Vascular Diseases 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Immunoproliferative Disorders 1Hemorrhagic Disorders 1Hematologic Diseases 1Cardiovascular Diseases 1Blood Protein Disorders 1

Interventions

Rituximab 12Cyclophosphamide 12fludarabine 8dacetuzumab 7blinatumomab 6Tacrolimus 6Busulfan 6Vincristine 5Prednisone 5Etoposide 5Doxorubicin 5Bortezomib 5fludarabine phosphate 4Valganciclovir 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Epoetin Alfa 4venetoclax 3ibrutinib 3Whole-Body Irradiation 3Methotrexate 3Melphalan 3Lenalidomide 3Ganciclovir 3Everolimus 3Dexamethasone 3Darbepoetin alfa 3Alemtuzumab 3tetulomab tetraxetan lu-177 2ponatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × ficlatuzumab × Lymphoid × Clear all
NCT00725634 2014-01-27

P05538

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
41 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡